Humanigen WKN: A2QEQW ISIN: US4448632038 Kürzel: HGEN Forum: Aktien Thema: Hauptdiskussion

On April 18, 2023, Humanigen, Inc. (the “Company”) was notified that it had been granted an extension until August 21, 2023 to demonstrate compliance with all applicable requirements for listing of the Company’s common stock on Nasdaq by the Nasdaq Hearings Panel (the “Panel”), subject to the Company’s compliance with the Panel’s requirements for periodic updates relating to the status of the Company’s progress against achievement of the compliance plan presented at the April 6, 2023 hearing with the Panel. There can be no assurance that the Company will be successful in its execution of its compliance plan or otherwise regain compliance with the applicable Nasdaq listing requirements within the extended compliance period.

Humanigen Presents Promising New Hematologic Data from PREACH-M Trial for Chronic Myelomonocytic Leukemia Treatment at the 2023 European Hematology Association Congress

Of the 14 participants enrolled and treated with lenzilumab plus azacitidine, ten are evaluable with three to eighteen months of follow-up and all ten have had a rapid clinical response Building upon previously reported positive clinical responses, these additional data demonstrate statistically significant and clinically relevant improvements in hematologic outcomes, along with improvements in inflammatory markers, that occur in the early months after treatment initiation and appear durable CMML is a rare, aggressive cancer; approximately 20% of patients survive three years from diagnosis No new CMML medications with novel mechanisms of action have been approved in over 30 years and hypomethylating agents, such as azacitidine alone, are currently considered "standard of care"

🤔

😁😀👍

Mittlerweile schon bei 2,xx

Wieso nur hinkt dieses ***** TR immer hinterher 🙈

Na dann alles Gute. Wo liegt denn Dein Ek?

Bei meinem EK lohnt es sich nicht zu verkaufen. Entweder delisting oder Rakete

Natürlich, bin immernoch dabei.

👍

https://www.nasdaq.com/press-release/humanigen-lenzilumab-being-studied-as-a-potential-first-treatment-in-thirty-years

Ist hier noch jemand dabei?

Humanigen, Inc. (the “Company”) confirmed today that its request for a hearing before a Nasdaq Hearings Panel (the “Panel”) to appeal the determination from the Nasdaq Listing Qualifications Department previously reported in the Company’s Current Report on Form 8-K filed on February 24, 2023 has been granted. The Company’s hearing before the Panel has been scheduled for April 6, 2023.

Das war eine Frage. Im 8k filling von august 22 steht etwas von 20.2.23